中国医学前沿杂志（电子版）2023，Vol.15Issue(11)：71-78,8.DOI:10.12037/YXQY.2023.11-11
贝利尤单抗治疗系统性红斑狼疮合并血栓性微血管病1例并文献复习
Belimumab in the treatment of systemic lupus erythematosus with thrombotic microangiopathy:a case report and literature review
摘要
Abstract
Objective To investigate the efficacy of belimumab on the treatment of systemic lupus erythematosus(SLE)complicated with thrombotic microangiopathy(TMA).Methods The clinical features of SLE patient with TMA treated by belimumab in the Rheumatology Department of Zhongshan People's Hospital were reported,and the outcomes of the patient were followed up.The relevant literature was reviewed and summarized.Results A total of 9 SLE patients with TMA were included.All of them were female with an average age of 34.3±15.9 years.All the patients had hematological damage,while 5 patients of them showed the nervous system damage,and four of them presented with kidney damage.3 patients underwent transrenal biopsy,which revealed type IV lupus nephritis(LN)with TMA,type IV + V LN with TMA,and type IV LN,respectively.Three patients were diagnosed with SLE and TMA,and six patients were diagnosed with SLE and thrombotic thrombocytopenic purpura(TTP).All the patients received glucocorticoid pulse therapy or high-dose glucocorticoids.Eight patients received plasma exchange,three patients received cyclophosphamide,and one patient received mycophenolate.Four patients received belimumab alone,and five patients received rituximab and belimumab sequentially.The clinical symptoms of all patients were improved after treatment,and no death case was reported.Conclusions SLE patients can be complicated with TMA,and the etiology is complex.Belimumab may be a novel and reasonable treatment strategy for SLE patients with TMA.关键词
贝利尤单抗/系统性红斑狼疮/血栓性微血管病Key words
Belimumab/Systemic lupus erythematosus/Thrombotic microangiopathy引用本文复制引用
邹婵娟,丁菱,王敏,王明霞,颜丝语,何善智..贝利尤单抗治疗系统性红斑狼疮合并血栓性微血管病1例并文献复习[J].中国医学前沿杂志（电子版）,2023,15(11):71-78,8.基金项目
Zhongshan Medical Research Project(20231A020041) 中山市医学科研项目(20231A020041) （20231A020041）
